This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-04 and is reviewed periodically as new material appears.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
On 12 March 2018, the UK government said that a Novichok agent had been used in an attack in the English city of Salisbury on 4 March 2018 in an attempt to kill former GRU officer Sergei Skripal and his daughter Yulia. British Prime Minister Theresa May said in Parliament: "Either this was a direct action by the Russian state against our country, or the Russian government lost control of its potentially catastrophically damaging nerve agent and allowed it to get into the hands of others." On 13 March the BBC asked Vladimir Putin if Russia was "behind the poisoning of" Skripal and he answered "Get to the bottom of it first then we can discuss it" while he delegated a spokesperson to claim that "a circus show in the British parliament" was the upshot. Boris Johnson, the Foreign Secretary, refused to shake hands with Russian ambassador Alexander Yakovenko as he expressed "outrage" over the attack. On the next day, the UK expelled 23 Russian diplomats after the Russian government refused to meet the UK's deadline of midnight on 13 March 2018 to give an explanation for the use of the substance. Addressing the United Nations Security Council on 15 March, Vassily Nebenzia, the Russian envoy to the UN, responded to the British allegations by denying that Russia had ever produced or researched the agents, stating: "No scientific research or development under the title Novichok were carried out." After the attack, 21 members of the emergency services and public were checked for possible exposure, and three were hospitalised. As of 12 March, one police officer remained in hospital.
. Moreover population dynamics like birth and death processes can be included. Such complex models enable a deeper understanding of infection dynamics and the introduction of different pharmaceutical and non-pharmaceutical interventions.
The Waitangi Tribunal releases an interim report urging the New Zealand Crown to halt work on the proposed Regulatory Standards Bill and to engage in "meaningful consultation" with Māori. Deputy Prime Minister Winston Peters, Regional Development Minister Shane Jones, Labour Party MP Ingrid Leary attend a reopening ceremony at Hillside Engineering. Pro-Palestine, transgender rights, pay equity and climate change protesters picket the event. 20 May: Foreign Minister Winston Peters joins 22 other foreign ministers and the European Union in calling on Israel to allow a full resumption of aid to the Gaza Strip. Two groups of protesters gather outside the New Zealand Parliament to call for the NZ Government to lower the bowel cancer screening age and oppose the suspension of three Te Pāti Māori MPs. The New Zealand Parliament votes to postpone a debate on the Privileges Committee's decision to suspend three Te Pāti Māori MPs until 5 June, allowing them to participate in an upcoming debate around the 2025 New Zealand budget. 22 May: Finance Minister Nicola Willis releases the 2025 New Zealand budget. The Wellington City Council votes to preserve the historic Begonia House and Khandallah Pool, while making cutbacks in transport infrastructure and renovations to Wellington Zoo. The Council also introduces parking fees for motorcycles in the Wellington CBD. 23 May – The New Zealand Geographic Board and Land Information Minister Chris Penk decline a proposal by the Kororāreka Marae Society to rename Russell to its Māori language name "Kororāreka".
== Career == After his PhD, Wüthrich continued postdoctoral research with Fallab for a short time before leaving to work at the University of California, Berkeley for two years from 1965 with Robert E. Connick. That was followed by a stint working with Robert G. Shulman at the Bell Telephone Laboratories in Murray Hill, New Jersey from 1967 to 1969. Wüthrich returned to Switzerland, to Zürich, in 1969, where he began his career there at the ETH Zürich, rising to Professor of Biophysics by 1980. He currently maintains a laboratory at the ETH Zürich, at The Scripps Research Institute, in La Jolla, California and at the iHuman Institute of ShanghaiTech University. He has also been a visiting professor at the University of Edinburgh (1997–2000), the Chinese University of Hong Kong (where he was an Honorary Professor) and Yonsei University. During his graduate studies Wüthrich started out working with electron paramagnetic resonance spectroscopy, and the subject of his PhD thesis was "the catalytic activity of copper compounds in autoxidation reactions". During his time as a postdoc in Berkeley he began working with the newly developed and related technique of nuclear magnetic resonance spectroscopy to study the hydration of metal complexes. When Wüthrich joined the Bell Labs, he was put in charge of one of the first superconducting NMR spectrometers, and started studying the structure and dynamics of proteins. He has pursued this line of research ever since. After returning to Switzerland, Wüthrich collaborated with, among others, Nobel laureate Richard R.
Sources: en.wikipedia.org
Pakistan and Bangladesh have experienced strained relations, particularly under the Awami League governments led by Sheikh Hasina, driven by her pro-India stance and historical grievances. Pakistan, a prominent member of the Organisation of Islamic Cooperation (OIC), prioritises maintaining cultural, political, social, and economic relations with Arab and other Muslim-majority nations in its foreign policy. In September 2025, Pakistan and Saudi Arabia signed a Strategic Mutual Defence Agreement under which any aggression against one country is considered an aggression against both, formalising a defensive commitment that also extends Pakistan's nuclear umbrella to Saudi Arabia.
=== Legal status === In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cibinqo, intended for the treatment of atopic dermatitis. The applicant for this medicinal product is Pfizer Europe MA EEIG. In December 2021, the European Commission approved abrocitinib for the treatment of atopic dermatitis. In January 2022, the US Food and Drug Administration (FDA) approved abrocitinib for adults with moderate-to-severe atopic dermatitis.
===== First generation ===== The Cronin–Gerow Implant, prosthesis model 1963, was a silicone rubber envelope-sac, shaped like a teardrop, which was filled with viscous silicone-gel. To reduce the rotation of the emplaced breast implant upon the chest wall, the model 1963 prosthesis was affixed to the implant pocket with a fastener-patch, made of Dacron material (polyethylene terephthalate), which was attached to the rear of the breast implant shell.
== Expression and possible function == FAP expression under physiological conditions is very low in the majority of adult tissues. FAP is nevertheless expressed during embryonic development, and in adults in pancreatic alpha cells in multipotent bone marrow stromal cells (BM-MSC) and uterine stroma. FAP expression is high in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. FAP is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis. Fibroblast activation protein (FAP) is overexpressed in a vast majority of neoplasms, particularly in more than 90% of epithelial tumors which could be an appropriate target for evaluation of tumor’s molecular and metabolic functions by FAP inhibitor (FAPI) ligands
==== Immunological biosensor ==== Gold nanoparticles have been coated with peptides and glycans for use in immunological detection methods. The possibility to use glyconanoparticles in ELISA was unexpected, but the method seems to have a high sensitivity and thus offers potential for development of specific assays for diagnostic identification of antibodies in patient sera.
Sources: en.wikipedia.org
=== Archaea === Archaea have a single type of RNAP, responsible for the synthesis of all RNA. Archaeal RNAP is structurally and mechanistically similar to bacterial RNAP and eukaryotic nuclear RNAP I-V, and is especially closely structurally and mechanistically related to eukaryotic nuclear RNAP II. The history of the discovery of the archaeal RNA polymerase is quite recent. The first analysis of the RNAP of an archaeon was performed in 1971, when the RNAP from the extreme halophile Halobacterium cutirubrum was isolated and purified. Crystal structures of RNAPs from Sulfolobus solfataricus and Sulfolobus shibatae set the total number of identified archaeal subunits at thirteen. Archaea has the subunit corresponding to Eukaryotic Rpb1 split into two. There is no homolog to eukaryotic Rpb9 (POLR2I) in the S. shibatae complex, although TFS (TFIIS homolog) has been proposed as one based on similarity. There is an additional subunit dubbed Rpo13; together with Rpo5 it occupies a space filled by an insertion found in bacterial β′ subunits (1,377–1,420 in Taq). An earlier, lower-resolution study on S. solfataricus structure did not find Rpo13 and only assigned the space to Rpo5/Rpb5. Rpo3 is notable in that it's an iron–sulfur protein. RNAP I/III subunit AC40 found in some eukaryotes share similar sequences, but does not bind iron. This domain, in either case, serves a structural function. Archaeal RNAP subunit previously used an "RpoX" nomenclature where each subunit is assigned a letter in a way unrelated to any other systems.
Aortic dissection (AD) occurs when an injury to the innermost layer of the aorta allows blood to flow between the layers of the aortic wall, forcing the layers apart. In most cases, this is associated with a sudden onset of agonizing chest or back pain, often described as "tearing" in character. Vomiting, sweating, and lightheadedness may also occur. Damage to other organs may result from the decreased blood supply, such as stroke, lower extremity ischemia, or mesenteric ischemia. Aortic dissection can quickly lead to death from insufficient blood flow to the heart or complete rupture of the aorta. AD is more common in those with a history of high blood pressure; a number of connective tissue diseases that affect blood vessel wall strength including Marfan syndrome and Ehlers–Danlos syndrome; a bicuspid aortic valve; and previous heart surgery. Major trauma, smoking, cocaine use, pregnancy, a thoracic aortic aneurysm, inflammation of arteries, and abnormal lipid levels are also associated with an increased risk. The diagnosis is suspected based on symptoms with medical imaging, such as CT scan, MRI, or ultrasound used to confirm and further evaluate the dissection. The two main types are Stanford type A, which involves the first part of the aorta, and type B, which does not. Prevention is by blood pressure control and smoking cessation. Management of AD depends on the part of the aorta involved. Dissections that involve the first part of the aorta (adjacent to the heart) usually require surgery.
Due to Monster's partnership and partial ownership by The Coca-Cola Company, Bang is now distributed through Coca-Cola's distribution network. The Chapter 11 proceedings of Vital Pharmaceuticals, Inc. and six affiliated debtors (Case No. 22-17842 ) were filed in the United States Bankruptcy Court for the Southern District of Florida before Judge Peter D. Russin. Berger Singerman LLP, led by partner Jordi Guso, and Latham & Watkins LLP served as co-counsel to the debtors, with Rothschild & Co retained as investment banker and Huron Consulting Group as financial advisor. The proceedings attracted significant creditor participation, with firms such as Conrad & Scherer LLP, Pachulski Stang Ziehl & Jones LLP, Mark S. Roher, P.A. of South Florida, and Bast Amron LLP representing various creditor interests and stakeholders throughout the sale process and plan confirmation. The brand's founder is a supporter of president Donald Trump, and has donated $250,000 to America First Action, a super PAC endorsed by Trump. Bang has been the subject of controversy for its attendance at Turning Point USA conferences, including a stunt in which the brand's marketers fired cash out of a "money cannon" towards the audience. The company also drew criticism for its response to the COVID-19 pandemic, ordering employees to attend a mandatory in-person meeting, a "dance party" promoting their Redline Noo-Fusion product, without proper social distancing or security protocols.
With the advent of the declaration and the British entry into Jerusalem on 9 December, the Vatican reversed its earlier sympathetic attitude to Zionism and adopted an oppositional stance that was to continue until the early 1990s.
Based on this, some physicians advocate using higher doses that may decrease the temperature by as much as 0.7 °C. Meta-analyses showed that paracetamol is less effective than ibuprofen in children (marginally less effective, according to another analysis), including children younger than 2 years old, with equivalent safety. Exacerbation of asthma occurs with similar frequency for both medications.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.